FibroScan
FibroScan 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Heart Failure、Heart Failure - NYHA II - IV。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
0 项
已进入 III/IV 期
12 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Echosens
- Valbiotis
- Weill Medical College of Cornell University
- Tanta University
- Assistance Publique - Hôpitaux de Paris
- The Cleveland Clinic
- Nanfang Hospital, Southern Medical University
- Vanessa Stadlbauer-Koellner, MD
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
加拿大、美国、Egypt、法国、中国、奥地利、丹麦、德国、中国台湾、South Korea、意大利、比利时
正在招募患者的 FibroScan 研究
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
不适用招募中加拿大NCT06704321Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
不适用招募中美国NCT05332613Metabolic Features Effects on FAST Score in MASLD Patients
不适用招募中EgyptNCT06867419Screening of Patients With Hepatic Fibrosis or Cirrhosis B and C
不适用招募中法国NCT06755632Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma
不适用招募中美国NCT06344143SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury
不适用招募中中国NCT06173947Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria
不适用招募中奥地利NCT06834178Identification of Liver Fibrosis Biomarkers
不适用招募中丹麦德国NCT06819917Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases
不适用招募中德国NCT06396871Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD
不适用招募中法国NCT04681573NAC- NAFLD And Cushing
不适用招募中法国NCT05881005The Effect of Survival, Response and Microbiota Change in Different Therapy Under Probiotic Supplement
不适用招募中中国台湾NCT06998823Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
II 期招募中中国NCT07481734Establishment of NAFLD Cohort and Development of Fibrosis Markers
不适用招募中South KoreaNCT02206841Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
不适用招募中中国NCT07632677Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database
不适用招募中美国NCT02897908Obeticholic Acid for Prevention in Barrett's Esophagus
II 期招募中美国NCT04939051The Olmsted NAFLD Epidemiology Study (TONES)
不适用招募中美国NCT04365855Type 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComes
不适用招募中法国NCT06567990Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis
不适用招募中意大利NCT07766135Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
不适用招募中丹麦NCT03308916Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures "Outside the Walls" by Dual Screening Method RTDs and FibroScan®
不适用招募中法国NCT06904820Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
不适用招募中比利时NCT06814600Development of a New Method for Liver Stiffness Measurement Using FibroScan
不适用招募中法国NCT06519331
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。